Compare SEER & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEER | ALDX |
|---|---|---|
| Founded | 2017 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.3M | 101.1M |
| IPO Year | 2020 | 2014 |
| Metric | SEER | ALDX |
|---|---|---|
| Price | $1.98 | $1.66 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 347.8K | ★ 2.3M |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 9.40 | ★ 40.43 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $16,578,000.00 | N/A |
| Revenue This Year | $2.14 | N/A |
| Revenue Next Year | $25.90 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 16.99 | N/A |
| 52 Week Low | $1.65 | $1.07 |
| 52 Week High | $2.41 | $6.18 |
| Indicator | SEER | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 63.86 | 32.59 |
| Support Level | $1.87 | $1.48 |
| Resistance Level | $2.13 | $1.89 |
| Average True Range (ATR) | 0.06 | 0.11 |
| MACD | 0.03 | 0.12 |
| Stochastic Oscillator | 80.52 | 43.90 |
Seer Inc is a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company operates in China, Australia, Eastern Europe, Israel, Japan and South Africa.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.